RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced an upcoming virtual Key Opinion Leader (KOL) event scheduled for Wednesday, October 30, 2024, at 10:00 AM ET. This event will focus on the unmet medical needs in uncontrolled and resistant hypertension, and the potential impact of lorundrostat, a promising aldosterone synthase inhibitor currently in development.
The event will feature insights from renowned medical experts including Dr. Luke J. Laffin from Cleveland Clinic, Dr. James M. Luther from Vanderbilt University Medical Center, and Dr. Rhian Touyz from McGill University Health Centre. Each will share their expertise on hypertension management and discuss how lorundrostat could revolutionize current treatment practices.
Lorundrostat is designed as a highly selective inhibitor targeting aldosterone synthesis, a key factor in hypertension. The drug has shown significant promise in reducing blood pressure among patients with uncontrolled or resistant hypertension during the Phase 2 Target-HTN trial. This trial demonstrated the drug’s potential to effectively lower blood pressure with manageable side effects.
The event will also provide an overview of the ongoing pivotal trials, Advance-HTN and Launch-HTN, which further explore lorundrostat’s efficacy. Attendees will have the opportunity to participate in a live Q&A session following the presentations, allowing for direct interaction with the experts.
Hypertension remains a major health concern, contributing to heart disease and stroke, and affects millions globally. Current treatments fail to adequately control blood pressure in a significant portion of patients. The introduction of lorundrostat could represent a critical advancement in addressing this widespread issue.
Mineralys Therapeutics invites healthcare professionals, researchers, and interested parties to join the virtual event to gain deeper insights into the future of hypertension treatment.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.